NovoFine
Device
Novo Nordisk Inc
Total Payments
$420,387
Transactions
31
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $379,897 | 5 | 0 |
| 2020 | $40,490 | 26 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $420,387 | 31 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Effect of GLP-1 receptor agonism on weight and caloric intake in subjects after sleeve gastrectomy | Novo Nordisk Inc | $204,947 | 0 |
| Interventional Study of GH replacement in retired Professional Football players with GHD | Novo Nordisk Inc | $176,993 | 0 |
| Clinical Efficacy and Safety of Using Liraglutide to Treat Weight Regain After Bariatric Surgery | Novo Nordisk Inc | $9,015 | 0 |
| Comparing Insulin Degludec vs Glargine Inpt & Post-discharge of Med/Surg pts with T2DM | Novo Nordisk Inc | $6,894 | 0 |
| A randomized controlled trial comparing IDegLira vs basal bolus in poorly controlled Type 2 diabetes | Novo Nordisk Inc | $6,629 | 0 |
| Clinical Characterization and Trial of Growth Hormone Treatment in Patients with Aggrecan Deficiency | Novo Nordisk Inc | $3,712 | 0 |
| Recombinant human growth hormone (rhGH): effects on metabolic profile, body composition and skeletal | Novo Nordisk Inc | $3,182 | 0 |
| A phase II, randomized, double blind, placebo controlled trial of liraglutide in Parkinsons disease | Novo Nordisk Inc | $2,652 | 0 |
| Glucagon-like Peptide-1 Receptor Agonists as Novel Pharmacotherapies for Nicotine Dependence | Novo Nordisk Inc | $2,121 | 0 |
| Transition from Basal/Bolus to Once-Weekly Subcu Semaglutide and Basal Insulin in T2DM | Novo Nordisk Inc | $1,856 | 0 |
| Semaglutide and Atherosclerosis Progression in DM | Novo Nordisk Inc | $1,326 | 0 |
| Liraglutide 3mg daily (Saxenda) in Obese or Overweight Patients with Severe Mental Illness | Novo Nordisk Inc | $1,061 | 0 |
Top Doctors Receiving Payments for NovoFine
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $420,387 | 31 |
Ad
Manufacturing Companies
- Novo Nordisk Inc $420,387
Product Information
- Type Device
- Total Payments $420,387
- Total Doctors 0
- Transactions 31
About NovoFine
NovoFine is a device associated with $420,387 in payments to 0 healthcare providers, recorded across 31 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk Inc.
Payment data is available from 2020 to 2022. In 2022, $379,897 was paid across 5 transactions to 0 doctors.
The most common payment nature for NovoFine is "Unspecified" ($420,387, 100.0% of total).
NovoFine is associated with 12 research studies, including "Effect of GLP-1 receptor agonism on weight and caloric intake in subjects after sleeve gastrectomy" ($204,947).